Compare SLMT & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLMT | VERU |
|---|---|---|
| Founded | 2000 | 1971 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 44.0M |
| IPO Year | 2022 | 1996 |
| Metric | SLMT | VERU |
|---|---|---|
| Price | $3.99 | $2.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | 78.9K | ★ 200.4K |
| Earning Date | 06-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,296,958.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.56 | $2.05 |
| 52 Week High | $24.05 | $7.33 |
| Indicator | SLMT | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 51.16 | 46.18 |
| Support Level | $3.63 | $2.12 |
| Resistance Level | $4.60 | $2.65 |
| Average True Range (ATR) | 0.33 | 0.10 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 69.20 | 30.39 |
Solmate Infrastructure Public Ltd is a Solana-based crypto infrastructure company with a strategic focus on Abu Dhabi. The group builds high-performance validators that lower latency, expand network reach, and position Abu Dhabi as a world-wide hub for Solana infrastructure. The company creates value by working with its partners to build infrastructure and real hardware for the crypto revolution. Its cutting-edge Solana staking infrastructure will help drive the adoption of the network in the Middle East.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.